Loading…

Charles River Laboratories (CRL) backlog: remaining performance obligations

How much revenue Charles River Laboratories already has under contract, how fast it converts, and who it is with.

Data as of .

Charles River Laboratories backlog history

$0$2B$4BDec 2022ul 2023Dec 2023Jun 2024Dec 2024Jun 2025Dec 2025Jun 2026Sep 2026Backlog (RPO)Trailing 12-month revenue
Remaining performance obligations at each quarter end (bars) against trailing twelve-month revenue (line).
Amounts in USD. Source: SEC XBRL filings.
Quarter endBacklog (RPO)TTM revenueCoverageCustomer prepayments
26 Sep 2026$675M$3.98B0.2 yrs$204M
27 Jun 2026$700M$4.00B0.2 yrs$203M
28 Mar 2026$702M$4.03B0.2 yrs$194M
27 Dec 2025$667M$4.02B0.2 yrs$256M
27 Sep 2025$649M$4.02B0.2 yrs$238M
28 Jun 2025$727M$4.03B0.2 yrs$268M
29 Mar 2025$782M$4.02B0.2 yrs$250M
28 Dec 2024$788M$4.05B0.2 yrs$283M
28 Sep 2024$804M$4.06B0.2 yrs$252M
29 Jun 2024$857M$4.08B0.2 yrs$247M
30 Mar 2024$920M$4.11B0.2 yrs$256M
30 Dec 2023$986M$4.13B0.2 yrs$273M

Questions

What is Charles River Laboratories's backlog?
Charles River Laboratories reported $675M of remaining performance obligations at 26 Sep 2026, up 4% from a year earlier and down 4% from the previous quarter. That is 0.2 years of trailing revenue already under contract. Book-to-bill last quarter: 0.97.
How fast does Charles River Laboratories's backlog turn into revenue?
Over the last twelve months Charles River Laboratories recognised revenue equal to about 586% of the backlog it started each quarter with.

About these numbers

Remaining performance obligations (RPO) are revenue a company has contracted but not yet recognised, as reported in its SEC filings (XBRL tag RevenueRemainingPerformanceObligation). Coverage = backlog ÷ trailing twelve-month revenue. Book-to-bill = (change in backlog + revenue) ÷ revenue. Conversion = revenue recognised ÷ the backlog at the start of each quarter, summed over four quarters. Counterparty values come from company filings and releases.